# US 2022/0289794 A1 · Synthetic antimicrobial peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0289794 A1
- Document ID: US20220289794A1
- Status: Published application
- Kind: A1
- Application number: 17/639,082
- Filed: 2020-08-31
- Published: 2022-09-15
- Earliest claimed: 2019-08-29
- Assignees: Ajk Biopharmaceutical, LLC
- Applicants: Ajk Biopharmaceutical, LLC
- Inventors: Keykavous PARANG; Rakesh TIWARI; Sandeep LOHAN; Eman MOHAMMED; Dindyal MANDAL
- Web page: https://patentgrep.com/patent/US20220289794A1

## CPC

- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A01N 25/26: in coated particulate form
- A01N 37/46: N-acyl derivatives
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 9/5115: {Inorganic compounds}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6927: {the form being a solid microparticle having no hollow or gas-filled cores}
- A61L 12/088: {Heavy metals}
- A61L 12/14: Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61P 31/04: Antibacterial agents
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 17/14: Peptides being immobilised on, or in, an inorganic carrier
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Synthetic peptides comprising a sequence of amino acids XnVm, wherein X represents positively charged amino acid, Y represents hydrophobic amino acid, and both n and m are greater than 2 are disclosed. In accordance with the purposes of the disclosed compositions and methods, as embodied and broadly described herein, the disclosed subject matter relates to synthetic antimicrobial peptides and methods of making and using same.

## Claims

### Claim 1

A synthetic peptide comprising a sequence of amino acids XnYm, wherein X represents positively charged amino acid, Y represents hydrophobic amino acid, and both n and m are greater than 2.

### Claim 2 (depends on 1)

The synthetic peptide of claim 1, comprising a linear arrangement of amino acids as (XnYm).

### Claim 3 (depends on 1, 2)

The synthetic peptide of claim 1 or 2, comprising a cyclic arrangement of amino acids as [XnYm].

### Claim 4 (depends on 1)

The synthetic peptide of claim 1, comprising a plurality of cyclic arrangements of amino acids as hybrid peptides (cyclic-linear) [Xn]Ym, or Xn[Ym], with cyclic peptides contain positively-charged residues or hydrophobic residues attached to linear hydrophobic or positively-charged residues

### Claim 5 (depends on 1)

The synthetic peptide of claim 1, comprising a plurality of cyclic peptides, wherein at least two of the plurality of cyclic peptides are coupled by a linker to form a cyclic peptide couplet [X]n[Y]m.

### Claim 6 (depends on 5)

The synthetic peptide of claim 5, wherein the cyclic peptide couplet comprises a first cyclic peptide comprising positively charged amino acids and a second cyclic peptide comprising hydrophobic amino acids.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The synthetic peptide of any one of claims 1 to 6, wherein both n and m range from 2 to 9.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The synthetic peptide of any one of claims 1 to 7, comprising a positively charged region and a hydrophobic region.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The synthetic peptide of any one of claims 1 to 8, further comprising one or more additional amino acids positioned between a positively charged amino acid and a hydrophobic amino acid.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The synthetic peptide of any one of claims 1 to 9, wherein positively charged amino acids of the peptide are identical species.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The synthetic peptide of any one of claims 1 to 9, wherein positively charged amino acids of the peptide are different species.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The synthetic peptide of any one of claims 1 to 9, wherein hydrophobic amino acids of the peptide are identical species.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The synthetic peptide of any one of claims 1 to 9, wherein hydrophobic amino acids of the peptide are different species.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The synthetic peptide of any one of claims 1 to 13, wherein positively charged amino acids are L- or D-optical isomers of naturally occurring positively charged amino acids.

### Claim 15 (depends on 14)

The synthetic peptide of claim 14, wherein positively charged amino acids are selected from the group consisting of arginine, lysine, histidine, and ornithine.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The synthetic peptide of any one of claims 1 to 13, wherein positively charged amino acids are selected from L- or D-isomers of non-naturally occurring positively-charged amino acids.

### Claim 17 (depends on 16)

The synthetic peptide of claim 16, wherein non-naturally occurring positively-charged amino acids are selected from the group consisting of an arginine with a modified side chain, C3-arginine (Agp), C4-arginine (Agb), lysine with a modified side chain, an ornithine with a modified side chain, a histidine with a modified side chain, diaminopropionic acid (Dap), diaminobutyric acid (Dab), an amino acid having a free side chain amino group, and an amino acid having a free side chain guanidine group.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The synthetic peptide of any one of claims 1 to 17, wherein hydrophobic amino acids are L- or D-optical isomers of naturally occurring hydrophobic amino acids.

### Claim 19 (depends on 18)

The synthetic peptide of claim 18, wherein hydrophobic amino acids are selected from the group consisting of tryptophan, phenylalanine, leucine, and isoleucine.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The synthetic peptide of any one of claims 1 to 17, wherein hydrophobic amino acids are L- or D-optical isomers of non-naturally occurring hydrophobic amino acids.

### Claim 21 (depends on 20)

The synthetic peptide of claim 20, wherein hydrophobic amino acids are selected from the group consisting of p-phenyl-L-phenylalanine (Bip), 3,3-diphenyl-L-alanine (Dip), 3,3-diphenyl-D-alanine (dip), 3(2-naphthyl)-L-alanine (NaI), 3(2-naphthyl)-D-alanine (naI), 6-amino-2-naphthoic acid, 3-amino-2-naphthoic acid, 1,2,3,4-tetrahydronorharmane-3-carboxylic acid, 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (Tic-OH), 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, modified D- or L-tryptophan; N-alkyl tryptophan, N-aryl tryptophan, 5-hydroxy-L-tryptophan, 5-methoxy-L-tryptophan, 6-chloro-L-tryptophan), fatty amino acids NH2—(CH2)x—COOH (x=1-20), and an N-heteroaromatic amino acid.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A use of a synthetic peptide of any one of claims 1 to 21, wherein the synthetic peptide is used in combination with an antibiotic compound.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A use of a synthetic peptide of any one of claims 1 to 21, wherein the synthetic peptide is used in conjugation with an antibiotic compound.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A use of a synthetic peptide of any one of claims 1 to 21, wherein the synthetic peptide is used in combination with an antiviral compound.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A use of a synthetic peptide of any one of claims 1 to 21, wherein the synthetic peptide is used in conjugation with an antiviral compound.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

An antimicrobial composition comprising:
a synthetic peptide of any one of claims 1 to 21; and
a nanoparticle,
wherein the synthetic peptide is combined with a nanoparticle.

### Claim 27 (depends on 26)

The antimicrobial composition of claim 26, wherein the synthetic peptide is noncovalently coated onto the nanoparticle.

### Claim 28 (depends on 26)

The antimicrobial composition of claim 26, wherein the synthetic peptide is covalently coupled to the nanoparticle.

### Claim 29 (depends on 26, 27, 28)

The antimicrobial composition of any one of claims 26 to 28, wherein the nanoparticle is a gold nanoparticle or a silver nanoparticle.

### Claim 30 (depends on 26, 27, 28, 29)

The antimicrobial composition of any one of claims 26 to 29, further comprising an antimicrobial compound.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26, 27, 28, 29, 30)

Use of a synthetic peptide of any one of claims 1 to 21 or the antimicrobial composition of any one of claims 26 to 30 for the treatment of an infection.

### Claim 32 (depends on 31)

The use of claim 31, wherein the infection is selected from the group consisting of a bacterial infection, a Gram-positive bacterial infection, a Gram-negative bacterial infection, a fungal infection, and a viral infection

### Claim 33 (depends on 31, 32)

The use of claim 31 or 32, wherein the infection is caused by a multidrug-resistant bacteria.

### Claim 34 (depends on 31, 32)

The use of one of claims 31 to 32, wherein the infection is caused by an organism selected from the group consisting of methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii, Enterococcus faecalis, Clostridium difficile, Klebsiella pneumonia, Escherichia coli, Streptococcus pneumoniae, Pseudomonas aeruginosa, Mycobacterium tuberculosis, Carbapenem-resistant Enterobacteriaceae (CRE) gut bacteria, Neisseria gonorrhea, Candida albicans, and Cryptococcus neoformans.

### Claim 35 (depends on 31, 32)

The use of claim 31 or 32, wherein the infection is caused by an organism selected from the group consisting of suitable DNA viruses include (but are not limited to) Herpesviruses, Poxviruses, Hepadnaviruses, and Asfarviridae. Suitable RNA viruses include (but are not limited to) Flavivirus, Alphavirus, Togavirus, Coronavirus, Hepatitis D, Orthomyxovirus, Paramyxovirus, Rhabdovirus, Bunyavirus, Filovirus, Retroviruses, and Retroviruses.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26, 27, 28, 29, 30)

A method of inhibiting or halting microbial growth, comprising applying a synthetic peptide of any one of claims 1 to 21 or the antimicrobial composition of any one of claims 26 to 30 in an amount effective to inhibit or halt microbial growth.

### Claim 37 (depends on 36)

The method of claim 36, comprising a step of applying the synthetic peptide to an animal, wherein the amount is selected to effective to inhibit or halt microbial growth in the animal.

### Claim 38 (depends on 36)

The method of claim 36, comprising a step of applying the synthetic peptide to a biofilm, wherein the amount is selected to effective to inhibit or halt microbial growth in the biofilm.

### Claim 39 (depends on 38)

The method of claim 38, wherein the biofilm comprises a Gram-positive bacteria.

### Claim 40 (depends on 38)

The method of claim 38, wherein the biofilm comprises a Gram-negative bacteria.

### Claim 41 (depends on 36)

The method of claim 36, comprising a step of applying the synthetic peptide to a food or food product, wherein the amount is selected to effective to inhibit or halt microbial growth in the food or food product.

### Claim 42 (depends on 36)

The method of claim 36, comprising a step of applying the synthetic peptide to an aqueous solution, wherein the amount is selected to effective to inhibit or halt microbial growth in the aqueous solution.

### Claim 43 (depends on 42)

The method of claim 42, wherein the aqueous solution is a water supply.

### Claim 44 (depends on 42)

The method of claim 42, wherein the aqueous solution is selected from the group consisting of an eyedrop, a contact lens solution, and an eye wash solution.

### Claim 45 (depends on 36)

The method of claim 36, comprising a step of applying the synthetic peptide to an article, and wherein the amount is selected to be effective to inhibit or halt microbial growth on or within the article.

### Claim 46 (depends on 45)

The method of claim 45, wherein the article is a personal article selected from the group consisting of a contact lens, a personal wipe, a baby wipe, a diaper, a wound dressing. a towelette, and a cosmetic product.

### Claim 47 (depends on 45)

The method of claim 45, wherein the article is a medical device.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26, 27, 28, 29, 30)

A composition comprising a synthetic peptide of any one of claims 1 to 21 or the antimicrobial composition of any one of claims 26 to 30, wherein the synthetic peptide comprises a non-peptide bond coupling two adjacent amino acids of the peptide.

### Claim 49 (depends on 48)

The composition of claim 48, wherein the non-peptide bond is selected from the group consisting of a thioamide, an N-methyl group, and a CH2—NH group.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26, 27, 28, 29, 30)

Use of a synthetic peptide of one of claims 1 to 21 or the antimicrobial composition of any one of claims 26 to 30 to inhibit or halt microbial growth in or on an animal.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26, 27, 28, 29, 30)

A kit comprising:
a synthetic peptide of any one of claims 1 to 21 or the antimicrobial composition of any one of claims 26 to 30; and
instructions for applying the synthetic peptide in a manner effective to inhibit or halt microbial growth.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26, 27, 28, 29, 30)

A pharmaceutical formulation comprising:
a synthetic peptide of any one of claims 1 to 21 or the antimicrobial composition of any one of claims 26 to 30; and
a pharmaceutically acceptable vehicle.

### Claim 53 (depends on 52)

The pharmaceutical formulation of claim 52, wherein the pharmaceutically acceptable vehicle is selected to provide at least one of topical, oral, inhalation, injection, rectal, vaginal, intravenous infusion, and nasal administration of the synthetic peptide.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26, 27, 28, 29, 30)

A method of increasing transport of a compound across a cell membrane, comprising application of a peptide of any one of claims 1 to 21 or the antimicrobial composition of any one of claims 26 to 30 to the cell membrane.

### Claim 55 (depends on 54)

The method of claim 54, wherein the compound is an antibiotic, an antifungal, or antiviral.

### Claim 56 (depends on 54, 55)

The method of claim 54 or 55, wherein the cell membrane is a bacterial cell membrane, viral cell membrane, or fungal cell membrane.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A pegylated form of a synthetic peptide of any one of claims 1 to 21.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26, 27, 28, 29, 30)

A pharmaceutical composition comprising a compound of any one of claims 1 to 21 or the antimicrobial composition of any one of claims 26 to 30, in an amount that is effective against a coronavirus.

### Claim 59 (depends on 58)

The pharmaceutical composition of claim 58 comprising a carrier or excipient.

### Claim 60 (depends on 58)

The pharmaceutical composition of claim 58, wherein the pharmaceutical composition is formulated as an injectable, a solid or semi-solid form, a tablet, a film, a gel, a cream, an ointment, a spray, a solution, a suspension, a micellar suspension, powder or granule, an encapsulated granule, an atomized mist, or a pessary.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A method of treating a bacterial disease, comprising:
obtaining a pharmaceutical formulation comprising a compound of any one of claims 1 to 21; and
applying an effective amount of the pharmaceutical formulation to an individual in need of treatment.

### Claim 62 (depends on 61)

The method of claim 61, wherein application comprises topical application of the pharmaceutical formulation to a body surface.

### Claim 63 (depends on 62)

The method of claim 62, wherein the body surface is a mucus membrane.

### Claim 64 (depends on 61)

The method of claim 61, wherein application comprises injection of the pharmaceutical formulation.

### Claim 65 (depends on 64)

The method of claim 64, wherein injection is selected from the group consisting of subcutaneous injection, intramuscular injection, intraocular injection, intravenous injection, and infusion.

### Claim 66 (depends on 61)

The method of claim 61, wherein application comprises inhalation of the pharmaceutical formulation.

### Claim 67 (depends on 61, 62, 63, 64, 65, 66)

The method of any one of claims 61 to 66, wherein treatment is prophylactic.

### Claim 68 (depends on 61, 62, 63, 64, 65, 66)

The method of any one of claims 61 to 66, wherein the individual has an active bacterial infection but is asymptomatic.

### Claim 69 (depends on 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 61 to 68, wherein the pharmaceutical formulation comprises a second active compound.

### Claim 70 (depends on 69)

The method of claim 69, wherein the second active compound is selected from the group consisting of an antiviral compound, an antibacterial compound, an antifungal compound, an anti-inflammatory compound, and a bronchodilator.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 70)

The method of claim 70, wherein the bacterial compound is a second compound as in one of claims 1 to 26.
